Spruce Street Capital LP
28 holdingsFiling period: 2026-03-31Current AUM: $464.0Mestimated from latest prices
| # | Ticker | Company | Shares | Reported Value | Current Value | % Portfolio | Change | Date |
|---|---|---|---|---|---|---|---|---|
| 1 | RLMD | RELMADA THERAPEUTICS INC | 6.26M | $43.0M | $32.8M | 7.07% | +2.18M | 2026-03-31 |
| 2 | — | KINIKSA PHARMACEUTICALS I | 761.1K | $36.6M | $36.6M | 7.90% | +326.1K | 2026-03-31 |
| 3 | LBRX | LB PHARMACEUTICALS INC | 1.38M | $33.6M | $54.7M | 11.79% | +370.6K | 2026-03-31 |
| 4 | DNTH | DIANTHUS THERAPEUTICS IN | 373.3K | $31.3M | $39.9M | 8.60% | +75.8K | 2026-03-31 |
| 5 | RLAY | RELAY THERAPEUTICS INC | 2.98M | $29.7M | $56.2M | 12.11% | -- | 2026-03-31 |
| 6 | ANRO | ALTO NEUROSCIENCE INC | 1.33M | $29.1M | $35.1M | 7.56% | +1.10M | 2026-03-31 |
| 7 | CNTA | CENTESSA PHARMACEUTICALS | 489.8K | $19.5M | $19.5M | 4.19% | +411.9K | 2026-03-31 |
| 8 | SVRA | SAVARA INC | 3.38M | $18.5M | $18.5M | 3.98% | +972.1K | 2026-03-31 |
| 9 | KALV | KALVISTA PHARMACEUTICALS | 897.7K | $18.1M | $18.1M | 3.89% | +509.7K | 2026-03-31 |
| 10 | PCVX | VAXCYTE INC | 245.7K | $14.3M | $13.3M | 2.86% | -154,651 | 2026-03-31 |
| 11 | ELVN | ENLIVEN THERAPEUTICS INC | 329.0K | $12.9M | $18.0M | 3.89% | -117,078 | 2026-03-31 |
| 12 | SRZN | SURROZEN INC COM NEW | 432.0K | $12.6M | $9.6M | 2.07% | -- | 2026-03-31 |
| 13 | ENTA | ENANTA PHARMACEUTICALS I | 932.6K | $11.8M | $11.8M | 2.53% | +542.9K | 2026-03-31 |
| 14 | — | ALKERMES PLC | 318.0K | $11.2M | $11.2M | 2.42% | -- | 2026-03-31 |
| 15 | CATX | PERSPECTIVE THERAPEUTICS | 2.63M | $11.0M | $7.6M | 1.65% | -- | 2026-03-31 |
| 16 | NERV | MINERVA NEUROSCIENC | 1.66M | $10.0M | $6.6M | 1.42% | -- | 2026-03-31 |
| 17 | IPSC | CENTURY THERAPEUTICS | 4.06M | $9.2M | $8.2M | 1.77% | +2.64M | 2026-03-31 |
| 18 | ALMS | ALUMIS INC | 392.6K | $8.6M | $11.1M | 2.39% | -- | 2026-03-31 |
| 19 | SABS | SAB BIOTHERAPEUTICS IN | 2.20M | $8.4M | $7.8M | 1.69% | -- | 2026-03-31 |
| 20 | ERAS | ERASCA INC | 422.5K | $6.8M | $7.7M | 1.65% | -3,467,089 | 2026-03-31 |
| 21 | IKT | INHIBIKASE THERAPEUTI | 3.58M | $6.0M | $7.8M | 1.68% | -- | 2026-03-31 |
| 22 | MAZE | MAZE THERAPEUTICS INC | 200.0K | $6.0M | $5.4M | 1.16% | -- | 2026-03-31 |
| 23 | ANTX | AN2 THERAPEUTICS INC | 1.66M | $5.6M | $8.7M | 1.88% | -- | 2026-03-31 |
| 24 | LXEO | LEXEO THERAPEUTICS INC | 928.6K | $5.3M | $3.8M | 0.83% | +753.6K | 2026-03-31 |
| 25 | — | HELIX ACQUISITION CORP III | 500.0K | $5.1M | $5.1M | 1.09% | -- | 2026-03-31 |
← Scroll →
Page 1 of 2